Immuno-oncology
Conference Coverage
Combination immunotherapy is active in dMMR/MSI-H metastatic colorectal cancer
With median follow-up of 13.4 months, 55% of metastatic CRC patients had a response to the combination of nivolumab and ipilimumab in the...
From the Journals
Checkpoint inhibitors look safe in rheumatology patients
The Mayo Clinic analysis examines 16 patients with rheumatologic diseases and cancer who received checkpoint inhibitor therapy.
Latest News
Immune-modified RECIST can help identify survival benefit from cancer immunotherapy
Analyses of early trials of atezolizumab for NSCLC and bladder cancer reveal aspects of immune-modified RECIST that seem to predict OS better than...
Conference Coverage
CRB-410 update: Multiple myeloma response rates remain high with bb2121 CAR T-cell therapy
ATLANTA – A novel CAR T-cell therapy that targets BCMA shows promising efficacy and safety in heavily pretreated patients with relapsed/refractory...
Conference Coverage
VIDEO - New lymphoma drug approvals: Clinical use, future directions
ATLANTA - At the ASH annual meeting, FDA representatives and clinicians discussed new lymphoma drug approvals and their use in the real-world...
Conference Coverage
PANACEA: pembrolizumab overcomes trastuzumab resistance for some
SAN ANTONIO – Pembrolizumab overcomes trastuzumab resistance in some HER2-positive advanced breast cancer if the tumor expresses PD-L1.
Conference Coverage
VIDEO: CAR T cell axi-cel drives B-cell lymphomas into remission
Dr. Sattva S. Neelapu describes efforts to manage adverse events common to CAR T-cell therapies, notably cytokine release syndrome.
Conference Coverage
Three-month response to CAR T-cells looks durable in DLBCL
ATLANTA – A quarter of the patients in the study were infused as outpatients.
Conference Coverage
Updated ZUMA-1 data show durable CAR-T responses in B-cell lymphomas
ATLANTA – Updated results in 108 patients with refractory B cell lymphomas showed an ORR of 82%, including 58% complete responses, after a median...
Conference Coverage
DNA vaccine + PD-1 blockade shows promise in mCRPC
NATIONAL HARBOR, MD. – Combining PD-1 pathway inhibition with a DNA vaccine led to antitumor changes in mCRPC patients in a randomized clinical...
Conference Coverage
VIDEO: Dr. Sherene Loi discusses PANACEA trial and implications for pembrolizumab use
SAN ANTONIO – The ORR was 15.2% in the phase 1b/2 PANACEA trial of pembrolizumab and trastuzumab in trastuzumab-resistant HER2+ advanced breast...